Gepotidacin Drug Asset Due Diligence Report 2026

This Gepotidacin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

203

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Gepotidacin can convert its Small molecule drug profile and Bacterial Top II x Bacterial top IV biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Gepotidacin (query alias: gepotidacin)
Modality / target	Small molecule drug; Bacterial Top II x Bacterial top IV; Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors
Highest global status	Approved
Originator	GSK Plc
Active developers	GlaxoSmithKline UK Ltd., GSK Plc, GlaxoSmithKline LLC

The MCP disease footprint includes Bacterial urinary infection, Gonorrhea, Bacterial Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05630833	Phase 3	Completed	380	Number of Participants With Therapeutic Response (TR) (Combined Per-participant Microbiological and Clinical Success) for Gepotidacin at the Test of Cure (TOC) Visit
NCT06597344	Phase 3	Completed	97	Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours)
NCT07371429	Phase 1	Not yet recruiting	20	AUC from time zero to the time of the last quantifiable concentration (AUC[0-t]) of gepotidacin

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3b, Open-label, Single-arm Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Phase 3; n=97; evaluation: not stated. Reported fields: -; Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours) = 54.4 Percentage of participants (95% Confidence Interval, 43.6 - 65.0); -

FDA-Approved Drugs-BLUJEPA-CLINICAL STUDIES

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: CRc = 44.0 % ; CRc = 47.0 % ; CRc = 51.8 %

A Phase III, Multicenter, Randomized, Active Reference, Double Blind, Double-dummy Study in Japanese Female Participants to Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

Phase 3; n=380; evaluation: not stated. Reported fields: -; -; Therapeutic Success = 69 Participants

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Gepotidacin addresses Bacterial urinary infection, Gonorrhea, Bacterial Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 203 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Bacterial Top II x Bacterial top IV records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-03	Sam Chun Dang Pharm expands strategic partnership with Dr. Reddy's Laboratories through liposomal drug collaboration	Approved	Financial terms not disclosed
2026-05-11	科兴制药与大光制药达成出海合作携手拓展眼科产品海外市场	Approved	Financial terms not disclosed
2026-04-24	爱科瑞思携手K2 Therapeutics，共推ACR246全球临床开发	Phase 1/2	US$730.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Gepotidacin for use in the treatment of bacterial prostatitis”. The milestone feed surfaced a patent-application signal described as “Gepotidacin formulation”. The milestone feed surfaced a patent-application signal described as “Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO